The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Pexidartinib (Brand name: Turalio)
- Manufactured by
Daiichi Sankyo, Inc
FDA-approved indication: August 2019, pexidartinib (Turalio) was approved for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
National Library of Medicine Drug Information PortalMedline Plus Health Information